• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    2/13/24 5:13:53 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RVMD alert in real time by email
    SC 13G/A 1 tv01819-revolutionmedicinesi.htm SCHEDULE 13G/A revolutionmedicinesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 3)*

    Name of issuer:  REVOLUTION Medicines Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  76155X100

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  76155X100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    211,918

    7.  SOLE DISPOSITIVE POWER

    14,296,521

    8.  SHARED DISPOSITIVE POWER

    337,870

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    14,634,391

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.93%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    REVOLUTION Medicines Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    700 Saginaw Drive
    Redwood City, CA 94063

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    76155X100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $RVMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RVMD

    DatePrice TargetRatingAnalyst
    7/16/2024$46.00 → $62.00Buy
    Needham
    7/12/2024$52.00Overweight
    Barclays
    7/8/2024$63.00Buy
    Jefferies
    4/12/2024$36.00 → $46.00Buy
    Needham
    4/10/2024$36.00 → $48.00Outperform → Strong Buy
    Raymond James
    3/11/2024$43.00Overweight
    Piper Sandler
    1/5/2024$31.00 → $34.00Neutral → Buy
    BofA Securities
    1/4/2024$41.00Outperform
    Wedbush
    More analyst ratings

    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Goldsmith Mark A exercised 37,000 shares at a strike of $0.54, increasing direct ownership by 9% to 465,720 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      7/2/25 4:11:45 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Horning Sandra was granted 3,142 shares, increasing direct ownership by 3% to 96,574 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      6/30/25 4:27:49 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Patel Sushil was granted 3,142 shares, increasing direct ownership by 16% to 23,090 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      6/30/25 4:27:19 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    SEC Filings

    See more
    • SEC Form 8-K filed by Revolution Medicines Inc.

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/27/25 4:05:55 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/24/25 7:05:20 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Revolution Medicines Inc.

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/18/25 4:23:13 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Revolution Medicines with a new price target

      Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $62.00 from $46.00 previously

      7/16/24 8:15:42 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays initiated coverage on Revolution Medicines with a new price target

      Barclays initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $52.00

      7/12/24 7:33:26 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Revolution Medicines with a new price target

      Jefferies initiated coverage of Revolution Medicines with a rating of Buy and set a new price target of $63.00

      7/8/24 8:13:53 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

      Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldo

      6/30/25 8:00:00 AM ET
      $RVMD
      $SMMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

      REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (NASDAQ:SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selecti

      6/30/25 8:00:00 AM ET
      $RVMD
      $SMMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

      Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debtCompany moving forward with independent global commercialization strategy to prioritize patient reach and maximize shareholder valueTransaction expands Revolution Medicines' financial resources and optionality with $1.25 billion of the $2 billion available at the company's discretionRevolution Medicines to host webcast today at 8:00 a.m. Eastern Time REDWOOD CITY, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-add

      6/24/25 7:00:00 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      12/9/24 4:15:16 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Financials

    Live finance-specific insights

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

      Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NA

      2/26/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

      Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ

      12/15/22 7:00:00 AM ET
      $GERN
      $MRNA
      $PFE
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

      REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies. Dr. Kim will serve as an independent director for the remaining term of Neil Exter, who is stepping down after serving as a director most recently since 2019

      7/13/22 7:00:00 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      11/8/24 10:52:39 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 6:30:27 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 9:26:21 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care